Combination of laser microdissection, 2D-DIGE and MALDI-TOF MS to identify protein biomarkers to predict colorectal cancer spread

Clinical Proteomics

  ^{1    1    2    2    3    3    4    5    6} 

[1] 0000 0000 8862 6892, grid.416979.4, Coastal and Coast District Health Board, Department of Surgery, Wellington Hospital, Wellington, New Zealand;0000 0001 2292 3111, grid.267827.e, Centre for Biodiscovery and School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand;0000 0004 0439 7957, grid.416918.3, Wakefield Biomedical Research Unit, Wakefield Clinic, Wakefield Hospital, Wellington, New Zealand;0000 0004 1936 7304, grid.1010.0, Discipline of Surgery, The Queen Elizabeth Hospital, Basil Hetzel Research Institute, University of Adelaide, 37a Woodville Road, 5011, Woodville, SA, Australia;0000 0004 1936 7304, grid.1010.0, Discipline of Surgery, The Queen Elizabeth Hospital, Basil Hetzel Research Institute, University of Adelaide, 37a Woodville Road, 5011, Woodville, SA, Australia;0000 0004 0439 7957, grid.416918.3, Wakefield Biomedical Research Unit, Wakefield Clinic, Wakefield Hospital, Wellington, New Zealand;0000 0004 1936 7830, grid.29980.3a, Department of Pathology and Molecular Medicine, Otago University of Wellington, Wellington, New Zealand;

关键词: Colorectal cancer;    Prognosis;    Biomarkers;    Proteomics;    Liver metastasis;   

DOI  :  10.1186/s12014-019-9223-7

来源: publisher

【 摘 要 】

Biomarkers are urgently required to support current histological staging to provide additional accuracy in stratifying colorectal cancer (CRC) patients according to risk of spread to properly assign adjuvant chemotherapy after surgery. Chemotherapy is given to patients with stage III to reduce the risk of recurrence but is controversial in stage II patients. Up to 25% of stage II patients will relapse within 5 years after tumor removal and when this occurs cure is seldom possible. The aim of this study was to identify protein biomarkers to stratify risk of spread of CRC patients. Laser micro-dissection was used to isolate cancer cells from primary colorectal tumors of stage II patients which did or did not metastasize within 5 years after surgical resection. Protein expression differences between two groups of tumors were profiled by 2D-DIGE with saturation CyDye labeling and identified using MALDI-TOF mass spectrometry. Evaluation of protein candidates was conducted using tissue micro array (TMA) immunohistochemistry on 125 colorectal tumor tissue samples of different stages. A total of 55 differentially expressed proteins were identified. Ten protein biomarkers were chosen based on p value and ratio between non metastasized and metastazised groups and evaluated on 125 tissues using TMA immunohistochemistry. Expression of HLAB, protein 14-3-3β, LTBP3, ADAMTS2, JAG2 and NME2 on tumour cells was significantly associated with clinical parameters related to tumour progression, invasion and metastasis. Kaplan–Meier survival curve showed strong expression of six proteins was associated with good CRC specific survival. Expression of HLAB, ADAMTS2, LTBP3, JAG2 and NME2 on tumour cells, was associated with tumour progression and invasion, metastasis and CRC specific survival may serve as potential biomarkers to stratify CRC patients into low and high risk of tumour metastasis. Combined methods of laser microdissection, 2D DIGE with saturation labelling and MALDI-TOF MS proved to be resourceful techniques capable of identifying protein biomarkers to predict risk of spread of CRC to liver.

【 授权许可】

CC BY